Latest news with #geneexpression
Yahoo
02-07-2025
- Business
- Yahoo
Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions
Reflects the Company's strategic focus on commercializing non-therapeutic proteins and unlocking long-term value from its C1 and Dapibus™ gene expression platforms JUPITER, Fla., July 02, 2025--(BUSINESS WIRE)--Dyadic International, Inc. ("Dyadic") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered input proteins for non-therapeutic applications in life sciences, food and nutrition, and industrial biotechnology utilizing its proprietary gene expression platforms, today announced that, effective in 30 days, it will be doing business as Dyadic Applied BioSolutions, marking a pivotal step in the company's transition from a research-driven organization to a commercially focused enterprise. The new name and revised visual identity reflect Dyadic's strategic emphasis on delivering applied biotechnology solutions through its patented and proprietary C1 and Dapibus™ gene expression platforms. The rebrand underscores Dyadic's focus on commercializing high value, non-therapeutic proteins that it believes are essential to life sciences, food, nutritional, and industrial bioprocessing applications. These proteins avoid the regulatory complexity and high costs associated with therapeutic biologics – enabling faster time to revenue, broader market reach, and long-term supply agreements. Recent significant milestones across both food and nutrition as well as fully funded legacy collaborations, discussed below, underscore Dyadic's strategic shift toward focusing on the commercial execution and market readiness of its C1 and Dapibus™ platforms. "As we evolve from licensing our technology in support of therapeutic and vaccine development into a revenue-focused bioprocessing protein platform business, our C1 and Dapibus™ production platforms remain the engines we expect to drive commercial execution," said Joe Hazelton, President and Chief Operating Officer of Dyadic. "The progress on our second non-animal dairy enzyme program – which recently triggered a $250,000 milestone payment – reflects the tangible outcomes of our new focus on commercialization. This rebranding reflects our top priority to deliver high-value input proteins at commercial scale." In parallel with its internal commercial focus, Dyadic continues to advance legacy collaborations with key global health partners. Dyadic recently achieved milestones in its partnership with the Gates Foundation, resulting in a second installment of $1.5 million in non-dilutive funding from a $3.0 million grant to further develop low-cost monoclonal antibodies (mAbs) for diseases such as malaria and RSV. Dyadic remains on track to commercialize its input proteins in 2025, and we believe Dyadic Applied BioSolutions is positioned to deliver sustained revenue and long-term value growth through its production platforms. About Dyadic Applied BioSolutions Dyadic Applied BioSolutions is a global biotechnology company focused on the scalable production of high-value, precision engineered input proteins for non-therapeutic applications across the life sciences, food and nutrition, and industrial biotechnology sectors. These proteins are expected to serve as essential components in bioprocessing, formulation, and product development, enabling innovation without the regulatory complexity and high costs associated with therapeutic biologics. Dyadic's proprietary microbial platforms are built on the industrially proven, highly productive and GRAS-accepted fungal host Thermothelomyces heterothallica. Its lead technology, the C1 Expression System, delivers precision engineered proteins and production strains that have redefined performance, scalability, and economy for life sciences and pharmaceutical applications. Dyadic's Dapibus™ platform is expected to further expand its capabilities into food, nutrition, wellness and industrial applications, offering rapid development and large-scale production of recombinant proteins and other biological inputs. For more information, visit Safe Harbor Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, including those regarding the Company's expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, including its strategic rebranding. Forward-looking statements involve many risks, uncertainties or other factors beyond the Company's control. These factors include, but are not limited to, the Company's history of net losses; the Company's capital needs; market and regulatory acceptance of the Company's microbial protein production platforms and other technologies, failure to commercialize the Company's microbial protein production platforms or the Company's other technologies; competition, including from alternative technologies; the results of nonclinical studies and clinical trials; changes in global economic and financial conditions; the Company's reliance on information technology; the Company's dependence on third parties; government regulations and environmental, social and governance issues; and intellectual property risks. For a more complete description of the risks that could cause the Company's actual results to differ from the Company's current expectations, please see the section entitled "Risk Factors" in the Company's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission (the "SEC"), as such factors may be updated from time to time in the Company's periodic filings with the SEC, which are accessible on the SEC's website and at All forward-looking statements speak only as of the date made, and except as required by applicable law, the Company assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in the Company's expectations. View source version on Contacts Dyadic Applied BioSolutionsPing W. RawsonChief Financial OfficerPhone: (561) 743-8333Email: ir@
Medscape
25-06-2025
- Health
- Medscape
Interferon-Driven Genes Signal Methotrexate Response in JIA
TOPLINE: Higher baseline expression of interferon (IFN)-driven genes was tied to a better response to methotrexate in patients with juvenile idiopathic arthritis. METHODOLOGY: Analysis of the link between blood biomarkers and response to methotrexate in 97 children (median age at baseline, 8.5 years; 62.9% women) with nonsystemic juvenile idiopathic arthritis (JIA). RNA sequencing was used to understand gene expression on CD4 + , CD8 + , CD14 + , and CD19 + cells and total peripheral blood mononuclear cells at baseline and at 6 months post-treatment with methotrexate. , CD8 , CD14 , and CD19 cells and total peripheral blood mononuclear cells at baseline and at 6 months post-treatment with methotrexate. The link between response to methotrexate therapy and gene activity in specific cell types was tested using the limma-voom, gene set enrichment analysis, and a new 51-gene score. Results were validated in 73 children with JIA, and pretreatment gene expression data were used to compare results with 240 adult patients with rheumatoid arthritis (RA). TAKEAWAY: Gene enrichment in the IFN-alpha (type I) and IFN-gamma (type II) response pathways was linked with treatment response in many cell types isolated from children with nonsystemic JIA. Higher baseline expression of both type I and type II IFN-driven genes was associated with a better response to methotrexate at 6 months post-treatment in JIA patients but not in adult RA patients. The 51-gene score, calculated from the expression levels of 51 specific IFN-response genes, was significantly higher in patients who responded to methotrexate than in those who did not (P = .00556). IN PRACTICE: 'It is possible that MTX [methotrexate] treatment is more effective in a distinct immunophenotype present across many International League of Associations for Rheumatology subtypes, where IFN-driven processes are dominant early in the disease,' the authors wrote. 'Our study provides proof of principle that carefully designed analyses can yield hope for a more precision-based approach to treatment in the future for children and families living with arthritis,' they added. SOURCE: This study was led by Melissa Kartawinata of University College London Great Ormond Street Institute of Child Health in London and Wei-Yu Lin of the University of Cambridge in Cambridge, both in England. It was published online on May 20, 2025, in Annals of the Rheumatic Diseases. LIMITATIONS: This study may have been underpowered to identify pathways with small but biologically significant influence on treatment response. Whole-blood RNA samples were unavailable to test the association between 51-IFN gene score and treatment response. Additionally, treatment response can fluctuate over time, and this study only analyzed outcomes at 6 months. DISCLOSURES: This study received support from the Medical Research Council, Versus Arthritis, Great Ormond Street Hospital Children's Charity, and Olivia's Vision. Additional support was provided by multiple organizations, including the Wellcome Trust and other sources. Several authors reported receiving funds and contributions in kind from various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
04-06-2025
- General
- Medscape
How Today's Human Brain Became so Uniquely Human
What unique processes conspire to create a healthy, functional human brain? How can we be so genetically similar to, say, chimpanzees, and yet be light-years more sophisticated cognitively and behaviorally? It may just come down to six cells. Evolutionary biologists who study the human brain and explore questions about why we're so different from other primates are especially interested in the contrasts between humans and chimpanzees. 'We share more than 99% of our DNA with chimpanzees, yet the human and chimpanzee brains are unique. That difference has always been very fascinating to me,' said Soojin Yi, PhD, professor in the Department of Ecology, Evolution, and Marine Biology at the University of California, Santa Barbara. Yi and colleagues recently published findings in the Proceedings of the National Academy of Sciences ( PNAS ) that help deepen scientists' understanding about what's behind our brain differences. They've found that 'there is more differential gene expression in human brains,' said Yi, referring to the activation of different genes within a single brain cell type that defines that cell's purpose. What's more, she said, 'Different brain cells follow different evolutionary paths depending on their unique roles in the brain.' New Findings While previous studies have suggested that human brain evolution is linked to accelerated changes in gene expression, Yi said many questions still remain. To explore how genes in different types of human brain cells have evolved compared with those of chimpanzees, the researchers used single-cell human and nonhuman primate (chimpanzee and rhesus macaques) transcriptomic data — messenger RNA transcripts present in a specific cell type — to analyze the unique molecular profiles (the gene activity) of six brain cell types. Yi said many single-cell research approaches had focused primarily on neurons, with relatively small numbers of nonneuronal cells, so their team aimed for a more diverse approach. 'To balance the brain cellular heterogeneity and statistical rigor,' she said that in addition to looking at excitatory and inhibitory neurons, they also looked at four glial cell types — astrocytes, microglia, oligodendrocytes, and oligodendrocyte precursor cells. Each of these cell types plays an important role in brain function and health. For example, excitatory neurons transmit signals between brain regions, inhibitory neurons help control brain activity, oligodendrocytes contribute to the formation of the myelin sheath around nerve fibers, and microglia are the brain's immune cells, always on the prowl for pathogens. Star-shaped astrocytes play a variety of roles, including maintaining the blood-brain barrier and supporting neurons. What They Learned 'Compared to chimpanzee brains, the human brain showed significant signs of accelerated regulatory evolution across all of the six major cell types in the brain,' said Yi, explaining that certain genes in human brain cells have evolved to produce more of certain proteins at a faster rate than in other primates. 'It's much more extensive than previously believed,' she said. Of the 25,000 genes involved in their analysis, Yi and colleagues were able to identify differences in the expression of about 5%-10% of the genes. When they considered cell subtypes, differences in expression leapt to 12%-15%. While the researchers expected to see more regulation than what was seen in previous studies, as well as some kind of cell-type specificity, Yi said, 'We didn't expect as much cell-type specificity as we saw.' 'What was really interesting to me was that when you compared cell types, genes that are differentially expressed in microglia are very different than genes that are differentially expressed in neurons,' said Yi. The findings support the belief held among many other researchers that there is 'a tremendous amount of diversity' among even the same types of brain cells in one part of the brain compared with another, Yi said. 'You may have the same cell type [such as a neuron], but it looks a little bit different in terms of transcript profiles depending on where it is located in the brain. I think that we cannot look at the brain from just a molecular perspective. We've got to really appreciate that the brain is an amalgam of many different cell types doing their own things while also working together to do these very complex functions that our brains are capable of,' said Yi. The authors pointed out study limitations, including the fact that data from nonhuman primates came from individuals living in captive facilities, which could affect their transcriptional profiles. Another Perspective In André Sousa's lab at the University of Wisconsin-Madison, the assistant professor of neuroscience and his colleagues study human brain development and evolution. 'We try to understand the mutations that have accumulated in human DNA after our split from our closest lineage — chimpanzees, bonobos, and gorillas — that can alter gene expression,' he said. Sousa, who was not involved in the PNAS study, said the new research adds another piece to the puzzle. 'I don't think it's an 'aha moment' in the sense that several studies before this had shown this abundance of genes that are more expressed in the human brain. But most of those studies were done at the bulk tissue level. The brain is very heterogeneous, and in bulk tissue studies, you can be diluting lots of signals,' he said. Because the new study analyzed single cells, he said, 'they found way more differentially expressed genes than previous studies. And we need to be a little bit careful because it could be a bias from the methodology because when you are analyzing single cells, you increase your statistical power.' Sousa said the results of the study left him pondering the fact that 'in general, more genes are more expressed both in chimpanzees and humans than genes that are lower expressed.' And that's interesting. 'I've been thinking about it quite a lot. Why do we see more genes going up than down in all of these species? We still don't know very much about what it means. It's hard to understand what's happening because it's very complex. It can have a lot of justifications, both molecularly, what's happening in the DNA, but also evolutionarily, what are the constraints that allow a gene to be more or less expressed?' he said. Sousa said he also found it interesting that the researchers subdivided certain cell types into subgroups. 'Even within subtypes, they saw accelerated evolution in terms of more upregulated genes in humans and chimpanzees than downregulated ones, and what the interesting thing they see is that the genes that are differentially expressed in each cell tend to be different. So they speculate that that probably reflects functional specialization of these cells in these species. It's a potential explanation. But it's impossible to know for sure from this data set and will require more research,' said Sousa. The authors hope to continue studying differential gene expression at the cellular level in both human and primate brains, especially the brain cell subtypes. But Yi said as scientists continue to piece together clues to what makes today's human brain so uniquely human, all animal brain evolution is fascinating. 'There are other species with awesome brains that are doing all these special things, too,' she said.
Yahoo
29-05-2025
- Business
- Yahoo
ARTHEx Biotech to Participate in the 2025 Jefferies Global Healthcare Conference
VALENCIA, Spain, May 29, 2025 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced today its participation in the 2025 Jefferies Global Healthcare Conference, being held June 3-5, 2025. Frédéric Legros, Executive Chairman and CEO, will participate in one-on-one meetings with investors during the conference. About ARTHEx BiotechARTHEx Biotech is a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression. The Company's lead investigational compound, ATX-01, is being evaluated for the treatment of myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I-IIa ArthemiR™ trial. ARTHEx is also advancing its in-house discovery engine to identify and develop microRNA modulators for other disorders with high unmet medical needs, including genetically-driven diseases like DM1. The Company headquarters are in Valencia, Spain. For more information, please visit and engage with us on LinkedIn. Company Contact. Investor and Media Contact Frédéric LegrosExecutive Chairman and CEOflegros@ +33679495790 Amy ConradJuniper Pointamy@ +1 858-366-3243 View original content to download multimedia: SOURCE ARTHEx Biotech Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
